CClinicalTrials.gg
Sign In
CompletedNCT01750723Updated Jul 9, 2013

Acetazolamide's Headache Inducing Characteristics and Effects on the Cerebral Arteries and Blood Flow

An interventional study of Acetazolamide in Headache and Migraine, sponsored by Danish Headache Center. Completed at 2 sites in Denmark. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-07-09.

Sponsored by Danish Headache Center · Not applicable, Interventional, and Basic science

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Study summary

In this study the investigators will research the hypothesis that the drug Acetazolamide induce headache and dilation of cerebral arteries and increase the cerebral blood flow in the areas of the brain supplied by these arteries.

Read the detailed description

To investigate headache score and accompanying symptoms during and after infusion of acetazolamide.

With magnetic resonance imaging the investigators will investigate changes in regional cerebral blood flow (rCBF) in the area supplied by middle cerebral artery (MCA), diameter of MCA, the Internal carotic artery (ICA), the superficial temporal artery (STA) and the Medial Meningeal artery (MMA).

02

Conditions studied

  • Headache
  • Migraine

Browse trials for

Keywords

  • Acetazolamide
  • Headache
  • Migraine
03

In context

Headache

1,226 studies on the registry are indexed under Headache; 202 are open to participants now.

This study's enrollment of 12 is below the median of 60 across 918 interventional studies indexed under Headache.

Browse Headache studies →

Lead sponsor

Danish Headache Center is the lead sponsor of 125 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Healthy volunteers
  • Aged 18-40
  • 50-100 kg
  • Fertile women must use safe contraceptives (IUD, oral contraceptives, surgical sterilisation and long lasting gestagen.

Exclusion criteria

Exclusion Criteria:

  • Tension type headache more than once/month
  • Other primary headaches
  • Daily medication except contraceptives
  • Drug taken within 4 times the halflife for the specific drug except contraceptives
  • Pregnant or lactating women
  • Exposure to radiation within the last year
  • Headache within the last 24 hours before start of trial
  • Hypertension
  • Hypotension
  • Respiratory or cardiac disease
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
12 participants (actual)

Study arms

  • Active comparator
    Acetazolamide

    Acetazolamide 1 g in 10 ml saline, i.v. infusion

    Drug: Acetazolamide

  • Placebo comparator
    Saline

    Saline, 10 ml i.v. infusion

Interventions

  • DrugAcetazolamide

    1 g diluted in 10 ml saline, i.v. bolus injection.

    Also known as: Diamox

06

What researchers measure

Primary outcomes

  1. Headache scores

    Comparison between Acetazolamide and placebo (saline).

    Time frame: 24 h

Secondary outcomes

  1. Artery circumference

    Acetazolamide induced changes in intracranial artery circumference before and after infusions.

    Time frame: Baseline, 30 min and 60 min

  2. Cerebral blood flow

    Acetazolamide induced changes in cerebral blood flow.

    Time frame: Baseline, 30 and 60 min.

07

Study locations

2 sites
  • Danish Headache Center
    Copenhagen, Glostrup 2600, Denmark
  • Department of Neurology
    Copenhagen, Glostrup 2600, Denmark
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 9, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01750723
Lead sponsor
Danish Headache Center
Responsible party
Nanna Arngrim (MD, medical doctor, Danish Headache Center) — Principal investigator
First posted
Dec 17, 2012
Start date
Dec 2012
Primary completion
Apr 2013
Completion
Apr 2013
Last update
Jul 9, 2013

Study contacts

Nanna Arngrim, MD
principal investigator · Danish Headache Center

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Headache→

Other studies from this sponsor

Danish Headache Center

Start the discussion